Best-read Articles of 2022
The Psychedelics Newsletter is the sector’s best-read investment focused newsletter, with over 25,000 subscribers. Featuring in-depth market analysis and interviews with industry thought leaders, the weekly publication tracks innovations and milestones to identify commercial opportunities.
As psychedelic medicines progress through clinical trials, attention is increasingly turning to the commercialisation and adoption of psychedelic healthcare. For drug developers this involves identifying the treatment’s expected patient journey and collaborating with regulators, healthcare providers and payees to promote accessibility.
As we look ahead to 2023, below is a summary of the six best-read articles from The Psychedelics Newsletter in 2022.READ MORE